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Comparison of Th1 cytokines and T cell markers gene expressions between virulent and
an attenuated EIAV vaccine strain
Talia Henkle, Chong Liu, David W. Horohov.
Gluck Equine Research Center, University of Kentucky
Abstract
The equine infectious anemia virus (EIAV) is closely related to HIV and has been used as
a model to identify protective mechanisms against lentivirus infection. In horses, EIA
infection progresses for about a year before infected horses manage to control virus
replication. This naturally-gained protection is absolutely dependent on active immune
responses as evidenced by the fact that immunosuppressive drugs can induce the
recurrence of disease. As the resolution of initial viremia correlates with the appearance
of virus specific cytotoxic T lymphocytes (CTL), we believe that cellular immune
responses play a key role in controlling EIAV in the horse. In a previous study, a
modified live EIAV stain (D9) provided effective protection against homologous virus
challenge without causing disease, but this vaccine could not achieve optimum protective
immunity until six months post vaccination. In this study, development of cell-mediated
immunity was monitored in EIAVD9 infected ponies over a six-month period. We
hypothesized that both Th1 cytokines and CTL would be upregulated in EIAVD9 infected
ponies. To test this hypothesis, ponies were inoculated with the attenuated EIAVD9 strain.
Whole blood samples were collected into PAXgene™ tubes weekly during the acute
infection stage (first 6 weeks) and at monthly intervals thereafter corresponding to the
chronic infection phase. Total RNA was isolated from the PAXgene™ tubes and gene
expression for both Th1 cytokine (IFN ) and CTL markers (Granzyme B and Perforin)
were determined using real-time PCR. At the same time, another group of ponies
receiving a virulent EIAV were monitored and sampled as comparison. We found that
Th1 cytokine (IFN ) and CTL marker (perforin) genes were significantly increased four
months post EIAVD9 infection. These results indicate that the maturation of cellular
immune response in EIAVD9 infected horses requires at least four months.
1. Introduction
Modified live or attenuated vaccines have been proven effective at preventing viral
diseases such as polio, measles, and smallpox (Mims, 1987). Since an attenuated vaccine
for HIV-1 is desired, work towards this goals has focused on closely related animal
lentiviruses (Craigo et al., 2007).
Equine Infectious Anemia Virus (EIAV) is a lentivirus that solely infects equids. EIAV
causes a globally prevalent chronic infection among equids, which makes the
development of a vaccine for EIAV an active area of research in equine veterinary
medicine (Capomaccio et al., 2012a; Capomaccio et al., 2012b; Craigo et al., 2007).
EIAV is transmitted via blood-feeding insect vectors, or via medical procedures such as
the use of virally contaminated needles(Capomaccio et al., 2012a; Capomaccio et al.,
2012b). EIAV manifests itself in three stages; acute, chronic, and inapparent. Once
infected with EIAV, the virus replicates within the equid for about 5 weeks before it can
be detected. Viremia is usually indicated by a fever, which occurs right before the equid
tests positive (Coggins Test). The acute signs of EIAV are fever, reduced platelet counts,

and a mild loss of appetite. The resolution of the acute phase is correlated with the
appearance of the virus specific cytotoxic T-lymphocytes (CTLs) (Capomaccio et al.,
2012a; Capomaccio et al., 2012b). After approximately 3-4 months the disease progresses
into the chronic phase which is characterized by recurring fever, pronounced platelet
reduction, ruptured blood vessels on mucous membranes, anemia, depression, and
swelling of limbs (Capomaccio et al., 2012a; Capomaccio et al., 2012b; Craigo et al.,
2007). More than 90% of horses progress into the life-long inapparent carrier phase 8-12
months post infection (Craigo et al., 2007). In this phase, viral load is tightly controlled
by the horse’s immune system and the horse becomes asymptomatic of EIAV infection.
Unlike equids and EIAV, humans possess no natural immunological protection
mechanisms against their respective lentivirus, HIV, which makes EIAV a unique and
valuable model for HIV research.
Over the past twenty years, a wide range of EIAV vaccines have been developed with
efficacies ranging from sterilizing immunity to profound enhancement of viral replication
(Craigo et al., 2007). In a previous study, a modified EIAV strain (D9) provided effective
protection against a homologous virus challenge without causing disease. However, this
vaccine could not achieve optimum protective immunity until six months post
vaccination (Craigo et al., 2007). This delay in the development of protective immunity
indicated that a maturation of the effector mechanism needed to occur. Analysis of
longitudinal serum from EIAV infected horses displayed a prolonged evolution of
envelope-specific antibodies responses, which are represented by avidity index,
conformational ratio, and neutralization titer, in EIAV infected horses (Hammond, 1997).
Cellular immune responses also play an important role in controlling EIAV infection as
the resolution of the acute phase is correlated with the appearance of the virus specific
CTL (Capomaccio et al., 2012a; Capomaccio et al., 2012b). The cell-mediated immune
response has not yet been thoroughly studied.
In this study, we aimed to monitor the kinetics of Th1 and CTL markers gene expressions
in EIAVD9 infected ponies over six months in order to provide new insights into cellular
immunity development in EIAVD9 infected ponies. Perforin and granzyme B are markers
for CTLs. Both are located in the secretory granules of activated CTLs. When CTLs kill
their target cells, perforin, a pore-forming protein, allows granzyme B to enter the
infected cell and activate the cellular apoptosis pathway (Lowin et al., 1994).
2. Materials and Methods
2.1 Experimental setup.
Eight ponies were inoculated with the EIAVUK strain as the control group and six ponies
were inoculated with the EIAVD9 vaccine. Approximately 3.0 ml of whole blood samples
were collected into PAXgene™ tubes at weekly intervals after inoculation for five weeks
and then monthly, for three months, 4 months after inoculation. PAXgene™ tubes
stabilize intracellular RNA in the blood sample.
2.2 Determination of Th1 cytokine (IFN ) and CTL markers (Granzyme B and
Perforin) gene expressions.

After the samples were collected, the tubes were incubated at room temperature for
approximately 24 hours and then stored at -20 C. Once ready to be processed the
samples were thawed. Total RNA was extracted from the samples using the PAXgene™
blood RNA extraction kit (Qiagen, Valencia, CA) using the protocol provided by the
manufacturer. The samples were then analyzed for RNA concentration using a
spectrophotometer. 1 g RNA was then dissolved in 41.5 l ribonuclease free water
(Qiagen, Valencia, CA) and then transcribed into cDNA using 38.5 l of reverse
transcription master mix (16 l AMV buffer [Promega], 16 l MgCl2 [25mM, Promega],
4 l dNTP [10mM; Promega], 1 l RNAsin [40 units/ml, Promega] 1 l oligo dT primer
[0.5 g/ml; Promega], 0.5 l avian myeloblastosis virus [AMV] reverse transcriptase
[20units/ml; Promega, Madison, WI]), as previously described (Coombs et al., 2006).
The reaction mixture was incubated at 42 C for 15 min and then 95 C for 5 min. The
cDNA was stored at -20 C until RT-PCR was performed.
The cDNA samples were then loaded onto 384-well plates in duplicate wells. Each well
contained 4.5 l cDNA and 5.5 l master mix (0.5 l 20 assay mix for primer/probe set of
interest [Applied Biosystems], and 5 l Sensimix [Bioline, Taunton, MA]) The gene
expressions of granzyme B, IFN , and perforin were then determined using RT-PCR
(ABI systems 7900 RT-PCR Instrument, Foster City, CA). The primer/probe sets were all
equine specific. The PCR reactions were initially incubated for 10 min at 95 C, followed
by 40 cycles of 95 C for 15s and 60 C for 60s. The internal PCR amplification
efficiencies were calculated in LinReg PCR (Ramakers et al., 2003). to confirm that the
application efficiencies exceeded 99%. To achieve relative quantification the CT
method (Schmittgen and Livak, 2008) was utilized to determine any changes in gene
expression. Beta-glucuronidase ( -GUS) was used as the endogenous control. The
average of the medium control samples of each horse were calculated and then used as
the calibrator for each target gene. The Relative quantity (RQ) was calculated using 2 CT
(Schmittgen and Livak, 2008). Gene expressions over 2 were viewed as positive.
3. Results
Th1 cytokines (IFN ) and CTL markers (GrzB and Perforin) genes were significantly
increased two weeks post infection in pathogenic EIAV infected group (Figure 1). This
correlates with the time of appearance of CTL response in previous studies. In contrast,
the EIAVD9 ponies (EIAV attenuated vaccine group) did not show any changes in gene
expressions early after inoculation. In comparison, IFN and perforin genes were
significantly increased four months post infection. This result indicated that the
maturation of cellular immune responses in D9 infected equines at least 4 months.
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Figure 1. Expression of Granzyme B mRNA in EIAV infected and EIAVD9 vaccinated ponies over a fivemonth period.

20

IFN

*

EIAV infected ponies

RQ

15

EIAV attenuated vaccine

10
5
0
1 week

2 week

3 week 4 month 5 month

Time Point
Figure 2. Expression or IFNγ mRNA in EIAV infected and EIAVD9 vaccinated ponies over a five-month
period.
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Figure 3. Expression of perforin mRNA in EIAV infected and EIAVD9 vaccinated over a five-month
period.
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Discussion:
The data indicated that the cellular immune system might play an important role in the
immunological control of EIAV as previously suspected. As previously stated, more than
90% of EIAV infected equids are able to effectively control viral replication after 8-12

months. EIAVD9 infected ponies, show no symptoms of infection (when not immunosuppressed) and are able to effectively protect against a challenge with the parental strain
of EIAV 6 months after vaccination. The EIAVUK virus used in this study has greater
virulence resulting in higher viral loads post challenge compared to the attenuated D9
strain. This likely resulted in greater stimulation of the immune response in the EIAVUK
recipients, as evidence by earlier expression of the immune related genes. Indeed, there
was increased expression of both perforin and granzyme B following infection with
EIAVUK before that seen in the EIAVD9 infected ponies. Nonetheless, the significant
upregulation of perforin in both groups of ponies at the 4 month mark indicates that
cellular immunity may be involved in the effective immune response to both viruses.
Exactly how the cellular immune system may be involved in the control disease is still
under investigation.
Understanding the immunological processes that are involved in controlling EIAV
replication in the inapparent carrier phase as well as horses vaccinated with EIAVD9 could
have global implications in the control of all lentiviral diseases, including those that are
prevalent in domestic animals as well as HIV in humans. Compared to pathogenic
viruses which cause recurring cycling of EIA, this attenuated D9 strain does not
cause any clinical EIA and could finally reach an optimum protective immunity six
months post infection. In this study, we found that EIAVD9 infected ponies did not show
significant IFN and perforin gene expressions until 4 months post infection. This slow
development of cellular immunity might correlate with the significantly decreased
replication of this attenuated virus in horse body (Craigo, 2005; Peng, 2005). Further
studies underlining the mechanisms related to the development of cellular
immunity in EIAVD9 infected ponies would provide useful information for improved
lentivirus vaccine design.
References
Capomaccio, S., Cappelli, K., Cook, R.F., Nardi, F., Gifford, R., Marenzoni, M.L.,
Passamonti, F., 2012a. Geographic structuring of global EIAV isolates: A
single origin for New World strains? Virus Research 163, 656-659.
Capomaccio, S., Willand, Z.A., Cook, S.J., Issel, C.J., Santos, E.M., Reis, J.K.P., Cook, R.F.,
2012b. Detection, molecular characterization and phylogenetic analysis of
full-length equine infectious anemia (EIAV) gag genes isolated from
Shackleford Banks wild horses. Veterinary Microbiology 157, 320-332.
Coombs, D.K., Patton, T., Kohler, A.K., Soboll, G., Breathnach, C., Townsend, H.G.G.,
Lunn, D.P., 2006. Cytokine responses to EHV-1 infection in immune and nonimmune ponies. Veterinary Immunology and Immunopathology 111, 109116.
Craigo, J.K., Durkin, S., Sturgeon, T.J., Tagmyer, T., Cook, S.J., Issel, C.J., Montelaro, R.C.,
2007. Immune suppression of challenged vaccinates as a rigorous
assessment of sterile protection by lentiviral vaccines. Vaccine 25, 834-845.
Craigo, J.K., F Li, JD Steckbeck, L Howe, SJ Cook, C Issel, RC Montelaro, 2005.
Discerning an effective balance between equine infectious anemia virus
attenuation and vaccine efficacy. Journal of Virology 79, 2666-2677.

Hammond, S., S J Cook, D L Lichtenstein, C J Issel and R C Montelaro, 1997.
Maturation of the cellular and humoral immune responses to persistent
infection in horses by equine infectious anemia virus is a complex and
lengthy process. . Journal of Virology 71, 3840-3852.
Lowin, B., Hahne, M., Mattmann, C., Tschopp, J., 1994. Cytolytic T-cell cytotoxicity is
mediated through perforin and Fas lytic pathways. Nature 370, 650-652.
Mims, C.A. 1987. The Pathenogenesis of Infectious Diseases (San Diego, Acedemic
Press).
Peng, B., LR Wang, VR Gomez-Roman, A Davis-Warren, DC Mentefiori, VS
Kalyanaraman, D Venzon, J Zhao, F Kan, TJ Towell, KK Murthy, I Srivastava,
SW Barnett, M Robert Guroff, 2005. Replicating rather than nonreplicating
adenovirus-human immunodeficiency virus recombinant vaccines are better
at eliciting potent cellular immunity and priming high-titer antibodies.
Journal of Virology 79, 10200-10209.
Ramakers, C., Ruijter, J.M., Deprez, R.H.L., Moorman, A.F.M., 2003. Assumption-free
analysis of quantitative real-time polymerase chain reaction (PCR) data.
Neuroscience Letters 339, 62-66.
Schmittgen, T.D., Livak, K.J., 2008. Analyzing real-time PCR data by the comparative
CT method. Nat. Protocols 3, 1101-1108.

